OTCMKTS:RHHBY

39.36
0.00 (0.00%) 1d
0

Related posts

3 Promising Oversold Stocks3 Value Euro StocksTop Stocks with Groundbreaking Potential in the DNS Manipulation and Gene-Editing Markets
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Experts have mentioned that Roche Holding recently acquired Carmot Therapeutics, a biotech company focusing on weight-loss drugs in phase 2 trials. This acquisition suggests that Roche Holding is looking to expand its portfolio in the weight-loss drug market, which is currently in high demand. The move indicates potential growth opportunities for Roche Holding in this sector and shows a strategic shift towards diversification in their drug pipeline.

Consensus
Positive
Valuation
Fair Value
COMMENT
Roche Holding

A month ago, they bought Carmot Therapeutics, a private clinical-stage biotech, though its drugs are only in phase 2 trials. Why did they buy this? So they can work on their own weight-loss drug, which are hot now.

Healthcare
BUY
Roche Holding
Great company. Diagnostic businesses helped through Covid. Some of the pipeline is coming off patent. Used free cashflow to buy back shares and to buy a few businesses. This will be the macro trend: buy pipelines, because they can't R&D drugs fast enough. 15x earnings, yield is 3%, not expensive. Only problem might be having to buy it on a foreign exchange.
Healthcare
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Roche Holding
The Swiss drugmaker has received FDA emergency approval to allow medical professionals to use its antibody test to determine if people have ever been infected with the virus. The test looks for antibodies in someone's blood that are used to fight off the virus that causes. Those exposed to Covid-19, even if they showed no symptoms, may have some immunity to it. The test would allow scientists to learn more about the disease, monitor how the Covid-19 is evolving, and help economies reopen. Roche plans to produce 60 million tests by the end of this month, while analysts expect the company to raise that to 100 million monthly by the end of the year. It looks like this news is already baked into the stock. Shares have returned to their mid-February peak, trading around $43-45. Roche Holding AG pays a 2.6% dividend with a forward PE of 13.69x. Revenue growth YOY stands at 5.48%.
Healthcare
PAST TOP PICK
Roche Holding

(A Top Pick October 31/17 Up 10%) A steady business that pays a good dividend. You should make 10% a year return. There is a good pipeline of drug projects yet to come. Yield 3.5%

Healthcare
DON'T BUY
Roche Holding

Made an acquisition quite a while ago of a biotech firm that comes up with all the future products. However, they are starting with some of the research that are in stage I and stage II. Sales were up 5% in the last quarter, but have seen a decline of 1% overall. The stock hasn't done a lot this year. Until this actually comes up with something that is going to be a gang buster, he would stay away.

Healthcare
TOP PICK
Roche Holding

A Swiss company. Has been a laggard this year, and pulled back recently. Have some interesting drugs for multiple sclerosis, immunology on cancer. Trades 15%-20% cheaper than the rest of the pharmas. Dividend yield of 3.6%. (Analysts' price target is CHF 261.00)

Healthcare
PAST TOP PICK
Roche Holding

(A Top Pick Oct 11/16. Down 2.05%.) A very deep pipeline of drugs and hidden value. It gives you a 3%+ yield. Great company.

Healthcare
TOP PICK
Roche Holding

Deep pipeline. Attractively valued. It has a couple of drugs that are nearing approval in the 1st half of this year. One is in the breast cancer area and one in the bio similar area. Dividend yield of 3.46%. (Analysts’ price target is CHF 278.65.)

Healthcare
BUY
Roche Holding

or RHHBY-5. You can buy the ADR. They have a strong pipeline and can grow it. He thinks they will continue to do well. When do you buy them considering the US election? Pharma do not do well before a US election. You buy these things going into the election and you get a bounce out of them.

Healthcare
TOP PICK
Roche Holding

Attractively valued at about 15X 2017 earnings. This has had 30 years of dividend growth. In addition to valuation, this has a very attractive pipeline with a hidden value of new products coming up. They also have a drug for multiple sclerosis that is due for regulatory action on December 28. Dividend yield of 3.39%.

Healthcare
DON'T BUY
Roche Holding

They don’t have enough products in the pipeline. Many pharmas are struggling right now.

Healthcare
COMMENT
Roche Holding

This is interesting right now based on the value proposition that is going into the pharma space. They have a lot of M&A activity there. This has some growth potential because of breast cancer. Fundamentally the company looks solid and the dividend looks good.

Healthcare
Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

Roche Holding(RHHBY-OTC) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Roche Holding is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Roche Holding(RHHBY-OTC) Frequently Asked Questions

What is Roche Holding stock symbol?

Roche Holding is a American stock, trading under the symbol RHHBY-OTC on the US OTC (RHHBY). It is usually referred to as OTC:RHHBY or RHHBY-OTC

Is Roche Holding a buy or a sell?

In the last year, there was no coverage of Roche Holding published on Stockchase.

Is Roche Holding a good investment or a top pick?

Roche Holding was recommended as a Top Pick by on . Read the latest stock experts ratings for Roche Holding.

Why is Roche Holding stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Roche Holding worth watching?

0 stock analysts on Stockchase covered Roche Holding In the last year. It is a trending stock that is worth watching.

What is Roche Holding stock price?

On 2024-07-22, Roche Holding (RHHBY-OTC) stock closed at a price of $39.36.